Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Champions Oncology, Inc. on October 14, 2024. The filing details the voting results for the election of directors, ratification of the independent auditor, and a non-binding advisory resolution on executive compensation.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing reports the following outcomes from the Annual Meeting:
- Election of Directors: All seven nominees were elected to one-year terms expiring at the 2025 Annual Meeting. Voting results varied, with Scott R. Tobin and Philip Breitfeld, MD receiving the highest support (over 9.1 million votes for) and Daniel Mendelson receiving the lowest support among nominees (7.7 million votes for).
- Auditor Ratification: Stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2025.
- Executive Compensation: The non-binding advisory resolution regarding the compensation of Named Executive Officers was approved.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is limited strictly to the tabulation of votes cast at the Annual Meeting.
Investor Verification Checklist
- Verify the specific vote counts for each director nominee to assess shareholder sentiment toward the board composition.
- Confirm the appointment of EisnerAmper LLP as the auditor for the fiscal year ending April 30, 2025.
- Review the 2024 Proxy Statement for detailed context on the executive compensation proposal that was approved.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.